Immix Biopharma, Inc. (NASDAQ:IMMX – Get Free Report) was the recipient of a significant growth in short interest in the month of September. As of September 30th, there was short interest totalling 552,800 shares, a growth of 15.2% from the September 15th total of 479,700 shares. Based on an average daily trading volume, of 144,200 shares, the short-interest ratio is presently 3.8 days. Approximately 3.4% of the company’s shares are short sold.
Immix Biopharma Trading Down 1.4 %
NASDAQ:IMMX traded down $0.02 during mid-day trading on Wednesday, hitting $1.44. The company had a trading volume of 98,889 shares, compared to its average volume of 187,247. Immix Biopharma has a 1 year low of $1.26 and a 1 year high of $7.75. The business has a fifty day simple moving average of $1.83 and a 200-day simple moving average of $2.10. The firm has a market capitalization of $38.04 million, a price-to-earnings ratio of -1.51 and a beta of 0.12.
Immix Biopharma (NASDAQ:IMMX – Get Free Report) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.06. As a group, research analysts anticipate that Immix Biopharma will post -0.64 earnings per share for the current year.
Institutional Inflows and Outflows
Analyst Ratings Changes
Separately, HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Immix Biopharma in a research note on Thursday, October 3rd.
Get Our Latest Stock Analysis on Immix Biopharma
Immix Biopharma Company Profile
Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.
Featured Stories
- Five stocks we like better than Immix Biopharma
- Breakout Stocks: What They Are and How to Identify Them
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- How Can Investors Benefit From After-Hours Trading
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is a support level?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.